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Maria Luisa Di Cecilia1, Gerardo Botti3 and Paolo Antonio Ascierto2Abstract
Background: Treatment of early and multiple cutaneous unresectable recurrences is a major therapeutic problem
with around 80% of patients relapsing within 5 years. For lesions refractory to elective treatments,
electrochemotherapy (ECT) involving electroporation combined with antineoplastic drug treatment appears to be a
new potential option. This study was undertaken to analyze the short- and long-term responses of lesions treated
with ECT with intravenous injection of bleomycin in melanoma patients with in-transit disease or distant
cutaneous metastases.
Methods: Between June 2007 and September 2012, 60 patients with relapsed and refractory cutaneous melanoma
metastases or in-transit disease underwent 100 courses of ECT with intravenous injection of bleomycin. Response to
treatment was evaluated three months after ECT. A long-lasting response was defined as no cutaneous or in-transit
relapse after a minimum of six months.
Results: Three months after ECT, a complete response was observed in 29 patients (48.4%), a partial response in 23
patients (38.3%) and no change or progressive disease in 8 patients (13.3%). The objective response rate of all
treated lesions was 86.6%. Thirteen patients (44.8% of complete responders) experienced a long-lasting response
after one ECT session and were disease-free after a mean duration of follow-up of 27.5 months.
Conclusions: The favorable outcome obtained in the present study demonstrates that ECT is a reliable, and
effective procedure that provides long-term benefit in terms of curative and palliative treatment for unresectable
cutaneous lesions without adversely impacting the quality of life of patients.
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Treatment of early and multiple cutaneous unresectable
recurrences is a major therapeutic problem with around
80% of patients relapsing within 5 years [1]. In-transit me-
tastases are cutaneous metastases that occur between a pri-
mary tumor and its regional lymphatic basin, with an
incidence that varies from <5% in patients without nodal
disease to 20% in cases with lymph node metastases [2].
The surgical excision of isolated lesions represents the
standard treatment, while isolated limb perfusion may be
adopted for multiple lesions involving the entire extremity.* Correspondence: dott.marone@virgilio.it
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reproduction in any medium, provided the orFor lesions refractory to elective treatments, electro-
poration appears to be a new potential therapeutic op-
tion. It is combined with intravenous administration of
antineoplastic drugs such as bleomycin, and is referred
to as electrochemotherapy (ECT). This study was under-
taken to analyze the short- and long-term responses of
melanoma patients with distant cutaneous metastases or
in-transit disease undergoing ECT with intravenous in-
jection of bleomycin. This is the first report to address
the long-term response of patients with melanoma
undergoing ECT.Methods
Between June 2007 and September 2012, 60 patients with
relapsed and refractory cutaneous melanoma metastases
or in-transit disease underwent one to five courses of ECTLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient and tumor characteristics
Characteristic Value
Age, median (range), years 62 (27–89)
Male/female, n 34/26
Breslow thickness, median (range), mm 5.0 (0.8-20.0)
Site of metastases, n
Trunk 21
Limbs 35
Head & neck 4




Table 2 Number of session of electrochemotherapy (ECT)
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injection of bleomycin according to the European Standard
Operating Procedures of Electrochemotherapy (ESOPE)
guidelines [3].
All treatments were performed using the Cliniporator™
device (IGEA Ltd., Modena, Italy) with two different
types of electrodes: type II for treatment of lesions in the
head and neck area and type III for all other sites. Elec-
tric pulses were delivered from 8 until 28 minutes after
intravenous injection of Bleomycin according to the
ESOPE standardized criteria. The required dose of bleo-
mycin was 15000 IU/m2; six (10%) patients had the dose
reduced because of decreased renal function or cardiac
disease. ECT was performed under general or loco-
regional anesthesia, dependent on the area being treated.
ECT treatment was performed after the approval of an
appropriate ethics committee (IEC of National Cancer
Institute of Naples, reference number 273/10) in compli-
ance with Helsinki Declaration, following internationally
recognized guidelines. All patients gave written informed
consent before each treatment.
Before ECT, the most significant lesions were measured
and photographed for each patient. Response to treatment
was evaluated three months after ECT in accordance with
World Health Organization (WHO) guidelines and de-
fined as progressive disease (PD) for lesions increased in
tumor size >25%, no change (NC) for lesions increased in
tumor size <25% or decreased <50%, partial response (PR)
for lesions decreased in tumor size >50% and complete re-
sponses (CR) for lesions that had disappeared. Patients
were assessed every 4 weeks for six months and thereafter
every three months. In the course of follow-up, the ap-
pearance of lesions in untreated areas was considered to
be new disease rather than a relapse of the previously
treated lesion. A further ECT session was proposed at least
6–8 weeks after the previous treatment in patients with le-
sions showing a PR. A long-lasting response was defined
as no cutaneous or in-transit relapse after a minimum
6 months.
Results
Clinical and pathological characteristics of patients are
summarised in Table 1. All patients had recurrent cuta-
neous disease after one or more previous radical surgical
treatments. Twenty-one patients had cutaneous or in-
transit disease of the trunk, 35 had in-transit disease of
an inferior limb and four patients had cutaneous disease
in the head and neck area. No patient had previously re-
ceived isolated limb perfusion or bleomycin.
A total of 100 courses of ECT were performed in the
60 patients; 34 patients had a single ECT session and 26
patients underwent ≥2 sessions of ECT, including one
patient who had five sessions (Table 2). The mean rate
of electrode application per patient was 73 and rangedfrom 8 to 187. The median duration of follow-up was
27.5 months (range 6–67 months). Treatment was well
tolerated with the most frequent side effects being non-
significant (i.e. mild) pain in 22 patients (36.6%) and
myalgia in 8 patients (13.3%). No systemic side effects
were observed. Necrosis of the treated lesions occurred
in 18 patients (30.0%), all of whom had received mul-
tiple sessions of ECT. Tattoo of needle electrodes
remained visible in the treated areas for about three
months.
Three months after the ECT session, 23 patients (38.3%)
had a PR and 29 had a CR (48.4%). Eight patients (13.3%)
had NC or PD. The objective response rate of all treated
lesions was 86.6%. A total of 13 patients (21.7% overall,
44.8% of those with a CR) experienced a long-lasting re-
sponse to ECT after one session and were free of disease
after a mean follow-up of 27.5 months (Figure 1).Discussion
Malignant melanoma is the seventh most common type of
cancer and the most common form of malignancy in
young adults. The spread of malignant melanoma occurs
by both lymphogenous and hematogenous routes. Local
recurrence, in-transit metastases and satellitosis represent
the same lymphatic dissemination process. The reported
5-year survival for patients with in-transit melanoma me-
tastasis is poor, ranging from12% to 37% [4].
Figure 1 Treatment response.
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mors can be a challenge because of their unresectability
and relative insensitivity to conventional systemic therap-
ies. Recurrence represents a treatment concern for the
physician and a source of distress and psychological bur-
den for the patient, whose quality of life may be adversely
affected by pain, ulceration, malodorous discharge and
bleeding associated with lesions.
In general, the goal of treatment should be the elimin-
ation of local and systemic disease without undue toxicities
or deformities, and with the consequent benefit of im-
proved life expectancy and quality of life. ECT is a non-
thermal tumor ablation modality, whereby the application
of electric currents on cancer tissue renders the cell mem-
brane permeable to non-or low permeant antineoplastic
drugs, thus potentiating their cytotoxic effect directly in-
side the cellular DNA. This temporary permeability of the
cell membrane caused by the electric pulses facilitates a
potent localized effect and magnifies the drug cytotoxicity
by several orders of magnitude [5-7]. Several cytotoxic
drugs have been tested with the best candidate for this type
of therapy appearing to be bleomycin. Neither electropor-
ation nor bleomycin alone inhibits tumour growth, but the
combination of both has a potent tumoricidal effect.
In preliminary reports, ECT with Bleomycin has been
shown to be effective for the palliative treatment of meta-
static cutaneous melanoma. In the ESOPE study, con-
ducted by a consortium of four cancer centers in Europe,
an objective response rate of 85% was achieved. A local
tumor control rate of 88% was obtained for ECT with
intravenous bleomycin, compared to 73% with intratu-
moral bleomycin and 75% with intratumoral cisplatinum.
These results indicated that the intravenous route provides
better results with minimal and tolerable side effects [8,9].
In a series of 14 refractory/relapsed patients with meta-
static cutaneous disease, Quaglino et al. reported a re-
sponse rate of 93% (13/14) after the first ECT, with a
complete regression in seven patients (50%). Repeating the
ECT procedure increased the response rate in the re-treated lesions (72%) with a local tumor control rate of
74.5% at 2 years [10]. Other reports also show the efficacy
of ECT in the treatment of in-transit or subcutaneous me-
tastases from cutaneous melanoma [11-13]. Recently,
Moller et al. reported an objective response rate of ap-
proximately 80–90% in the palliative management of
unresectable recurrent disease [14]. Kis et al. reported
their experience with the use of ECT with bleomycin in
158 cutaneous and subcutaneous metastases from nine
patients with cutaneous melanoma, in which an objective
response rate of 62% was achieved [15]. Colombo et al.
concluded that ECT is easy to perform and provides a
good quality of life and economic benefits without the po-
tentially undesirable side effects of systemic chemotherapy
[16]. ECT has also been shown to rapidly stop bleeding in
patients with bleeding cutaneous lesions, thereby improv-
ing quality of life [17].
A long-term complete response of cutaneous or sub-
cutaneous metastases is believed to be difficult to obtain
because of the intralymphatic spread of tumor cells. When
surgical excision is not feasible due to the extension of the
cutaneous disease, isolated limb perfusion could be an
option, but its complexity and generally short duration
of disease-free interval limits its indication [18]. Snoj et al.
reported a long-lasting response in melanoma treated with
ECT obtained with an easy, fast and effective procedure
which can be repeated as much as need as shown by our
study [19]. We found that approximately half of patients
with a CR at 3 months (44.8%) maintained a long-lasting
response (mean follow-up of over 2 years). This is the first
study to report long-term response after ECT in patients
with relapsed or refractory cutaneous melanoma.
Conclusions
Treatment of early and multiple unresectable cutaneous re-
currences of melanoma is a major therapeutic problem.
The favorable outcome obtained in the present study shows
that ECT is a reliable, easy, fast and effective procedure that
provides benefits in terms of curative and palliative treat-
ment for unresectable cutaneous lesions without adversely
impacting on the quality of life of patients.
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